3 Cancer Treatment Stocks to Buy Right Now
Healthcare companies that develop cancer treatments have an exciting opportunity ahead of them. According to the research firm EvaluatePharma, cancer drugs will generate more revenue than any other therapeutic area through 2024. Investors can benefit from this trend by purchasing shares of companies that focus in part -- or exclusively -- on cancer treatments.
With that in mind, here are three cancer treatment stocks you should consider buying right now: Bristol-Myers Squibb (NYSE: BMY), Merck (NYSE: MRK), and Exelixis (NASDAQ: EXEL).
Bristol-Myers has long been a leader in cancer treatment. The company's current lineup includes Opdivo, which was first approved by the Food and Drug Administration in 2014 for advanced melanoma (skin cancer). Since then, Opdivo has earned a plethora of new indications, including as a treatment for lung cancer, lymphoma, head cancer, and neck cancer.
Source Fool.com
